Ana Z.
Penezić
,
Vesna B.
Jovanović
,
Ivan D.
Pavićević
,
Jelena M.
Aćimović
and
Ljuba M.
Mandić†
*
Department of Biochemistry, Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, Belgrade 11158, Serbia. E-mail: ljmandic@chem.bg.ac.rs; Tel: +381 11 333 66 76
First published on 24th August 2015
The potential of carbonylation with methylglyoxal to alter HSA's binding affinity for copper(II) ions and its influence on the release of copper(II) ions from copper–HSA complexes were studied. The affinity of HSA to coordinate copper(II) decreased upon carbonylation of the Cys34-SH group. Carbonylation of copper–HSA complexes caused a decrease in Cys34-SH content, conformational changes and the release of copper(II) ions. The ratio between the percentage of reduction in the Cys34-SH group content and the percentage of release of copper(II) from complexes is 2.12 ± 0.28. Because the same ratio (1.96 ± 0.36) was obtained upon oxidation of the Cys34-SH group (with no changes in HSA conformation), the binding/release of copper (II) by HSA depended mainly on the redox state of the Cys34-SH group. The contents of Cys34-SH and HSA-bound copper(II) ions in the diabetic group (0.457 ± 0.081 mol SH per mol HSA, 10.7 ± 0.01 mmol per mol HSA, resp.) were significantly lower (p < 0.01) compared to the control group (0.609 ± 0.027 mol SH per mol HSA; 13.4 ± 0.01 mmol per mol HSA, resp.). Very strong correlations between the values for HSA-SH and glycated haemoglobin, HbA1c, (R = −0.803, p < 0.01), and between the values for the HSA-bound copper(II) content and HSA-SH content (R = 0.841, p < 0.002) were found in the diabetic group. Thus, HSA carbonylation leads to decrease in HSA-SH content and to the impairment of its copper(II) binding capacity that could contribute to further enhancement of oxidative and carbonyl stress in diabetes (as well as in other diseases with carbonyl stress).
Oxidative and/or carbonyl stress are believed to play an important role in pathogenesis of various diseases e.g. uraemia,8 renal failure, diabetes mellitus9,10etc. as well as in genesis of secondary complications in diabetic patients involving microangiopathies and cardio-vascular complications.11
HSA has 35 Cys residues, 34 of them being involved in 17 intramolecular disulfide bridges, and one, Cys-34, that is redox active. With normal serum concentration between 35 and 50 g L−1, and 70–80% of its Cys34 in the reduced/sulfhydryl form, HSA represents the predominant serum protein and a major plasma antioxidant.1,2,12 Antioxidant properties of HSA depend on nucleophilic properties of Cys34 as well as on copper-binding ability.2,13 Both of these attributes may become impaired when HSA is exposed to increased glycation, leading to protein modification, formation of advanced glycated end-products (AGEs) and protein cross-linking.14–18
Diabetes mellitus is one of the most prevalent chronic diseases, affecting around 360 million people worldwide,19 of which ∼90–95% are categorized as type 2.20 Hyperglycemia in diabetes provokes Maillard reaction, formation of Schiff bases, and Amadori products, and finally leads to generation of AGEs.21
Methylglyoxal (MG) represents a naturally occurring α-oxoaldehyde, generated either non-enzymatic, or from the spontaneous decomposition of triose phosphates, by autoxidation of carbohydrates, and glucose degradation, or by several minor metabolic pathways including the Maillard reaction and lipid peroxidation. The formation rate of MG in normal systems is 120 μmol per day, but several studies have shown that this rate in diabetes is increased by 5- to 6-fold.22,23 Because of its high reactivity (20000-fold more reactive than glucose24), MG represents a potent modifying agent of proteins14,18 and nucleic acids.25
Thus, studies related to diabetic pathology reveal the existence of oxidative stress in these patients, decreased content of the Cys34 thiol group,26 elevated levels of serum MG and copper(II) ions, especially in type 2 diabetics.27,28 Recent studies regarding MG as modifying agent of HSA (in vitro and in diabetes), and the ability of glycated HSA to bind of copper(II) ions reported different opposite results.29,30 Besides decrease in HSA-SH group content, carbonylation with MG leads to conformational changes in HSA molecules,31 which could also influence HSA copper binding. Therefore, the goal of this study was to determine the potential of MG, as a modifying agent, to alternate HSA's binding affinity for copper(II) ions, i.e. the potential of reaction of carbonylation to release copper(II) ions from copper–HSA complexes. The changes in the Cys34 thiol group content and in the content of copper(II) ions bound to HSA, and their ratios, as well as the changes in conformation of HSA and copper–HSA complexes during carbonylation in vitro (with MG) and in diabetes type 2, were monitored. Deciphering the effect of HSA modification with MG on its ability to bind and sequester copper(II) ions in circulation could prove useful in treating secondary complications in diabetic patients.
Spectrophotometric measurements were performed using a Beckman DU-50 spectrophotometer (Fullerton, CA, USA). Fluorescence spectra were obtained on a Fluoromax-4 Jobin Yvon (Horiba Scientific, Japan) spectrofluorimeter.
In order to investigate the influence of HSA carbonylation on copper(II) binding affinity, mercapto-HSA (with 0.879 mol SH per mol HSA) was pre-incubated with 10 mM MG for 24 h at 37 °C. The obtained carbonylated HSA (HSA-MG; with the thiol group content of 0.587 mol SH per mol HSA), as well as each mercapto and commercial HSA (0.400 mol SH per mol HSA) were incubated with three different concentrations of copper(II) ions (0.05, 0.10 and 0.20 mol of copper(II) per mol HSA). These Cu(II) concentrations were used because we wanted to have one (nearly) physiological, one slightly elevated and one supra-physiological saturation in order to be able to relate to physiological and pathological conditions during carbonylation with MG, and see if there is a significant difference in Cu(II) binding capacity of HSA. The content of bound copper in thus formed copper–HSA complexes I, II and III (resp.) was determined (Table 1). The mercapto-HSA sample (with 0.879 mol SH per mol HSA) is able to bind all available copper(II) ions. On the other hand, commercial HSA with 0.400 mol SH per mol HSA binds 14.4%, 15.6% and 29.9% less copper(II) ions than mercapto-HSA. These results suggested that the copper binding capacity of HSA is positively correlated with HSA-SH content, which is in accordance with the results of Zhang and Wilcox36 who found that both in vitro and in vivo Cu(II) ions preferently bind to albumin with reduced Cys34. The redox state of Cys34 was found to affect the chemical environment of His3, located ∼20 A away37 included in copper coordination besides the N-terminal amine and the first two deprotonated amides.
Copper–HSA complex | The content of Cu(II) ions bound to | Decrease in the content of Cu(II) ions bound to HSA (%) | |||
---|---|---|---|---|---|
Mercapto-HSA (mol per mol HSA ± SD) | Commercial HSA (mol per mol HSA ± SD) | HSA-MG (mol per mol HSA ± SD) | Commercial HSA vs. mercapto-HSA | HSA-MGavs. mercapto-HSA | |
a HSA-MG, HSA carbonylated with methylglyoxal. | |||||
I | 0.0512 ± 0.0035 | 0.0438 ± 0.0034 | 0.0434 ± 0.0013 | 14.4 | 15.2 |
II | 0.0959 ± 0.0038 | 0.0809 ± 0.0021 | 0.0810 ± 0.0021 | 15.6 | 15.5 |
III | 0.2025 ± 0.0042 | 0.1420 ± 0.0064 | 0.1655 ± 0.0019 | 29.9 | 18.2 |
In comparison to mercapto-HSA, carbonylated HSA samples (with 0.587 mol SH per mol HSA) bind copper(II) ions with reduced capacity (15.2%, 15.5% and 18.2% resp.) (Table 1).
This capacity reduction could be the consequence of decrease in the thiol group content, and also of the conformational changes in HSA (as Lys and Arg residues are also targeted during protein modification with MG).15 The changes in the three-dimensional structure were confirmed by recording the fluorescence emission spectra (Fig. 1).
Due to carbonylation of the HSA molecule, the quenching of internal fluorescence (originating from Trp214 after excitation of HSA molecule at 295 nm) at λem = 346 nm by 46% compared to the unmodified HSA was observed. The differences in fluorescence intensity of HSA and HSA-MG do not arise from changes in their secondary structure (far-UV CD spectra are not shown).
These results confirmed alterations in the capacity of HSA with low HSA-SH content to bind to copper(II) ions. The reaction of carbonylation leads to decrease in HSA copper(II) binding affinity, having important implications considering the involvement of free copper ions in the development of oxidative stress in diabetes (and other diseases with carbonyl stress).
Sample | HSA-SH content following 24 h incubation (mol SH per mol HSA) | Decrease in HSA-SH content compared to mercapto-HSA (%) | Content of HSA bound Cu(II) ion (mol per mol HSA) | Decrease in Cu(II) ion content (%) | |
---|---|---|---|---|---|
0 h | 24 h | ||||
Mercapto-HSA | 0.800 ± 0.046 | 8.9 | — | — | — |
Copper–HSA I | 0.818 ± 0.030 | 6.9 | 0.0511 ± 0.0035 | 0.0496 ± 0.0035 | 2.9 |
Copper–HSA II | 0.788 ± 0.030 | 10.3 | 0.0979 ± 0.0038 | 0.0920 ± 0.0015 | 6.0 |
Copper–HSA III | 0.746 ± 0.028 | 15.1 | 0.2025 ± 0.0042 | 0.1855 ± 0.0032 | 8.4 |
Mercapto-HSA-MG | 0.587 ± 0.049 | 33.2 | — | — | — |
Copper–HSA I-MG | 0.600 ± 0.021 | 31.7 | 0.0511 ± 0.0035 | 0.0432 ± 0.0042 | 15.5 |
Copper–HSA II-MG | 0.586 ± 0.041 | 33.3 | 0.0979 ± 0.0038 | 0.0814 ± 0.0033 | 16.8 |
Copper–HSA III-MG | 0.538 ± 0.060 | 38.8 | 0.2025 ± 0.0042 | 0.1675 ± 0.0019 | 17.3 |
The incubation of mercapto-HSA for 24 h at 37 °C, leads to decrease in HSA-SH content for almost 9%, caused by aerobic oxidation of the Cys34 free thiol group. The decrease in the thiol group content obtained for copper–HSA complexes I, II and III was different (6.9%, 10.3% and 15.1% resp.).
These changes implied the existence of the correlation between the thiol group content and the amount of bound copper ions. In order to perceive if this decrease is caused by binding of copper(II) ions (during preparation of complexes I, II and III) or, is the consequence of aerobic oxidation, or both, the content of HSA-SH groups of copper–HSA complexes obtained by incubation of mercapto-HSA with five copper concentrations (0.05, 0.08, 0.10, 0.16 and 0.20 mol Cu(II) per mol HSA) during 40 min, was tested (Table 3).
Content of Cu(II) ions incubated with mercapto-HSA (mol per mol HSA) | Content of HSA-SH groups after incubation of mercapto-HSA with Cu(II) ions (mol per mol HSA) | Decrease in the HSA-SH group content | |
---|---|---|---|
(mol SH per mol HSA) | (%) | ||
0.05 | 0.828 ± 0.003 | 0.051 ± 0.003 | 5.8 |
0.08 | 0.806 ± 0.005 | 0.073 ± 0.006 | 8.3 |
0.10 | 0.802 ± 0.010 | 0.077 ± 0.011 | 8.8 |
0.16 | 0.779 ± 0.004 | 0.100 ± 0.003 | 11.4 |
0.20 | 0.759 ± 0.008 | 0.120 ± 0.008 | 13.7 |
These data showed that loading HSA with copper(II) ions leads to decrease in Cys34 free thiol group content, and that this decrease is proportional to the concentration of copper(II) ions (a Pearson's correlation coefficient R = 0.996, Fig. 2A).
Comparison of thiol group changes obtained after 40 min (complex time preparation, Table 3) and 24 h (incubation time, Table 2) showed no significant differences (5.8%, 8.8% and 13.7% vs. 6.9%, 10.3% and 15.1%). Thus, it could be concluded that binding of copper(II) ions to HSA leads to decrease in the Cys-thiol group content. These results suggest that copper(II) ions, during the course of forming complexes with HSA molecules, could cause the oxidation of Cys34 (and thus affect the redox state of HSA34). Densitometric analyses of gel obtained by native-PAGE of mercapto-HSA and copper–HSA complex II (Fig. 2B) showed an increase of 10% in the intensity of the dimer band in copper–HSA complex II, compared to the dimer band present in mercapto-HSA. This percent corresponds to the percent of decrease in the thiol group content obtained after 24 h of incubation (10.3%), suggesting that copper(II) ions cause oxidation of free Cys34-thiol groups into a disulfide bridge formed between two HSA molecules.
The carbonylation of mercapto-HSA (HSA-SH content 0.879 mol per mol HSA, control) with MG for 24 h caused a decrease in HSA-SH content of 33.2% (Table 2), which is in accordance with the previously published data.15 A similar decrease in the content of HSA-SH groups was obtained for copper–HSA complexes (I-MG, II-MG and III-MG: 31.7%, 33.3% and 38.8%, resp.). However, when the decrease in HSA-SH content caused by the preparation of the copper–HSA complexes (I, II and III), is taken into account, it can be noticed that the percentage of HSA-SH groups which react with MG is lower (24.8%, 23% and 23.6%, resp.). The decrease in the Cys34-thiol group content resulted in the reduction of HSA-bound copper(II) ion content of 15.5%, 16.8% and 17.3% resp. (Table 2). Thus, copper(II) ions are released from HSA molecules during their carbonylation with MG. In order to test if carbonylation of the Cys34 free thiol group is the underlying cause for the release of copper(II) ions from copper–HSA complexes during incubation with MG, the HSA-bound copper(II) and the Cys34-SH group contents were measured in aliquots taken from the incubation mixture (Fig. 3A). The time course curve of Cys34-SH group carbonylation is similar to the copper releasing curve. The release of copper(II) ions occurred in the first three to four hours of the incubation of HSA–copper(II) complex with MG. The ratios between the percentage of reductions (Cys34-SH group content/HSA bound copper) upon HSA carbonylation were in the range from 0.21 to 2.1 (Fig. 3B).
These results show that similar to copper binding, the release of copper(II) from copper–HSA complexes during carbonylation is strongly dependant on the redox state of the Cys34-thiol group. In addition, it should be underlined that the percentage of decrease in HSA bound copper content, obtained during copper binding capacity investigations of carbonylated HSA-MG (15.2%, 15.5% and 18.2% resp., Table 1) and the percentage of copper release from copper–HSA-MG complexes during carbonylation (15.5%, 16.8% and 17.3% resp.) are almost equal. This result would be expected if decrease in thiol group content was considered to be the only cause of observed HSA binding capacity changes, as in both experiments the same concentration of MG was used. Nevertheless, since Cu(II) ion forms strong tetragonal complexes with biological nitrogen ligands (which is important for fast exchange of ligands in terms of intracellular transfers of this metal38) the observed release of copper(II) ions bound to HSA could also be the consequence of HSA conformational changes due to carbonylation. The conformational changes in HSA-MG and copper–HSA-MG obtained by florescence spectroscopy, i.e. quenching of internal fluorescence at λem 346 by 46.3% and 44.1% (resp.) are nearly identical in comparison to unmodified mercapto-HSA (Fig. 1). The ratio between the percentage of reduction in the Cys34 thiol group content due to carbonylation of copper–HSA complexes and the percentage of release of copper from complexes is 2.12 ± 0.28 (Table 4). The value of this ratio, obtained when oxidation of the thiol group (1.96 ± 0.36) occurs, is almost equal to the value obtained after carbonylation of the thiol group with MG. Because the HSA conformation and Cys34-SH accessibility39 are changed during carbonylation, but not after HSA-SH oxidation (Fig. 1), these results indicate that the binding/release of copper (II) ions by HSA depends mainly on the redox state of the free thiol group. Thus, if the Cys34 residue becomes carbonylated with MG, the copper(II) binding capacity of HSA reduces, and copper(II) ions are released from the complex copper–HSA-MG. The increase in flux of MG and the other reactive dicarbonyl compounds (glyoxal and 3-deoxyglucosone) occurring during carbonyl stress (in diabetes, Alzheimer's disease, renal failure, liver cirrhosis, anemia, uremia, and atherosclerosis)40 could lead to the Cys34 side chain carbonylation and therefore to the decrease in HSA-SH and HSA-bound copper contents. This, also, implicates the question of the correlation between these two parameters under real physiological conditions.
Thiol group | Decrease in HSA-SH content (%) | Decrease in the Cu(II) ion content (%) | Ratio | Ratio mean value |
---|---|---|---|---|
Oxidation | 6.9 | 2.9 | 2.38 | 1.96 ± 0.36 |
10.3 | 6.0 | 1.71 | ||
15.1 | 8.4 | 1.80 | ||
Carbonylation | 24.8 | 12.9 | 1.92 | 2.12 ± 0.28 |
23.0 | 11.5 | 2.00 | ||
23.6 | 9.7 | 2.44 |
Diabetic patients | Control | |
---|---|---|
*p < 0.05, compared to control group; **p < 0.01, compared to control group. | ||
n | 11 | 10 |
HbA1c (%) | 10.25 ± 1.52* | 5.59 ± 0.53 |
Total serum Cu2+ (μM) | 34.3 ± 8.1 | 28.5 ± 1.7 |
Total serum-SH (mM) | 0.330 ± 0.059** | 0.427 ± 0.037 |
HSA-SH (mol SH per mol HSA) | 0.457 ± 0.081** | 0.609 ± 0.027 |
Copper–HSA (mmol per mol HSA) | 10.7 ± 0.01** | 13.4 ± 0.01 |
HbA1c content in the diabetic group was significantly higher (p < 0.05) compared to the control group. In the HSA sample isolated from the serum of diabetic persons (diabetic), the quenching of internal fluorescence at λem = 346 nm (originating from Trp214 after excitation of the HSA molecule at 295 nm) by 23%, compared to the HSA of healthy person (control), was observed (Fig. 1). Thus, HSA glycation in hyperglycemia leads to change in HSA conformation. In addition, AGEs show fluorescence after excitation at λexc higher than 290 nm, i.e. they have characteristic excitation at wavelengths in the range of 328 to 370 nm and fluorescence emission from 378 to 440 nm. The monitoring of the fluorescence at λeksc/λem = 365/44041 or 370/43042 was suggested as an indicator of the protein glycation level. Fluorescence emission spectra of HSA samples isolated from the serum of healthy (control) and diabetic persons (Fig. 4), recorded in the wavelength range of 380 to 500 nm following excitation at 365 nm, are the approval that HSA modification occurred.
The total serum copper(II) ion content in diabetic patients was higher than in the control group, which is in accordance with the results of several studies.43,44 In contrast, the total serum thiol content was lower. The HSA-SH group content in the diabetic group is 24.9% lower compared to the control group, which is in accordance with the results from in vitro experiments and with our previously reported HSA-thiol group content decrease in diabetes.32 This difference is statistically significant (p < 0.01). As it was expected, based on in vitro experiments, the content of HSA-bound copper(II) ions in the diabetic group was also significantly lower (p < 0.01) in comparison to the control group. Decreased levels of HSA-bound copper(II) ions in diabetes were also found by Guerin-Dubourg et al.30 When the ratio between the percentages of decrease in the Cys34-SH group content and HSA bound copper content in the diabetic group were compared to the control, the values from 0.51 to 2.54 were obtained (almost identical to the above given in vitro results).
There is a negative correlation between the values for HSA-SH content and the HbA1c fraction, as well as for total serum thiol content and HbA1c fraction (R = −0.803, p < 0.01; R = −0.716, p < 0.05 resp.) in the diabetic group. In contrast, very good positive correlation (R = 0.841, p < 0.002) between the HSA-SH group contents and values of HSA-bound copper(II) ions was found in the diabetic group. These results confirm our hypothesis that modification of the HSA molecule in patients with diabetes type 2 causes a decrease in the Cys34 thiol group content, leading to the impairment of its copper(II) binding capacity. The increase of the free copper(II) ions in serum could contribute to the increase of reactive oxygen species.2 Free copper(II) can react with hydrogen peroxide (via the Fenton reaction) leading to the formation of hydroxyl radicals 60 times faster than iron.2 Free copper(II) ions increase glucose autoxidation, causing formation of the shorter-chain reactive carbonyl compounds,45 and acceleration of alpha-oxoaldehyde formation from early glycation products.46 On the other hand, as the HSA-SH group constitutes an important redox regulator in extracellular compartments,47 its decrease due to carbonylation leads also to the decrease of HSA antioxidative potential.48 Thus, carbonylation of HSA-SH leads to consequences that cause further enhancement of oxidative and carbonyl stress.
Footnote |
† PhD Department of Biochemistry, Faculty of Chemistry, University of Belgrade, P.O. Box 51, Studentski trg 16, 11158 Belgrade, Serbia. |
This journal is © The Royal Society of Chemistry 2015 |